Physician profile
Alan Goldenberg
NPI 1144280827
$3,791.53
in general payments reported to CMS, 2019-2025
17 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,094 · 2022: $129 · 2023: $13.54 · 2024: $140 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $3,036.67 | 2019-2025 | Korlym |
| Abbott Laboratories | $147.72 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.84 | 2022 | |
| Amgen INC. | $113.81 | 2024-2025 | Tepezza, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $110.02 | 2022-2025 | Recorlev |
| Madrigal Pharmaceuticals | $37.27 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $28.98 | 2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $27.42 | 2024 | Unithroid |
| Novo Nordisk INC | $26.18 | 2025 | Ozempic, Rybelsus |
| Valeritas, INC. | $25.27 | 2019 | |
| Tandem Diabetes Care, INC. | $24.46 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $24.27 | 2025 | Isturisa |
| Lilly USA, LLC | $22.22 | 2025 | |
| Insulet Corporation | $20.33 | 2025 | Omnipod |
| Beta Bionics, INC. | $16.53 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13.54 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Goldenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.